Impact of laboratory testing for heparin-induced antibodies: Using Bayes' rule to prevent overdiagnosis of heparin-induced thrombocytopenia

LaboratoriumsMedizin

Volumn 35, Issue 1, 2011, Pages 45-54

  Warkentin, Theodore E ^a,c   Cook, Richard J ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF WATERLOO   (Canada)

^c HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

Author keywords

Bayes; heparin induced platelet activation (HIPA) test; heparin induced thrombocytopenia (HIT); platelet factor 4 (PF4); thrombocytopenia; thrombosis

Indexed keywords

ADENOSINE DIPHOSPHATE; HEPARIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; THROMBOCYTE FACTOR 4;

ARTICLE; BAYES THEOREM; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNOASSAY; IN VITRO STUDY; LABORATORY TEST; OPTICAL DENSITY; SURGICAL PATIENT;

EID: 79953896673     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/JLM.2010.019     Document Type: Article

References (36)

1. Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia (4th edition). New York: Informa Healthcare USA, 2007:67-116.
2. Warkentin TE. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb Res 2003;110:73-82. (Pubitemid 37329444)
3. Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 2007;82:1037-43. (Pubitemid 350209843)
4. Greinacher A, Juhl D, Strobel U, Wessel A, Lubenow N, Selleng K, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007;5:1666-73. (Pubitemid 47091409)
5. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986;67:27-30. (Pubitemid 16167006)
6. Polgar J, Eichler P, Greinacher A, Clemetson KJ. Adenosine diphosphate (ADP) and ADP receptor play a major role in plate- let activation/aggregation induced by sera from heparin-induced thrombocytopenia patients. Blood 1998;91:549-54. (Pubitemid 28053377)
7. Warkentin TE, Sheppard JA. Testing for heparin-induced thrombocytopenia antibodies. Transfus Med Rev 2006;20:259-72. (Pubitemid 44428106)
8. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991;66:734-6.
9. Warkentin TE, Sheppard JI. Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists. Platelets 1999;10: 319-26. (Pubitemid 29490859)
10. 7RIIA. Blood 2001;98:2442-7.
11. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344:1286-92. (Pubitemid 32372963)
12. Warkentin TE, Sheppard JA, Moore JC, Cook RJ, Kelton JG. Studies of the immune response in heparin-induced thrombocytopenia. Blood 2009;113:4963-9.
13. Warkentin TE, Hayward CP, Smith CA, Kelly PM, Kelton JG. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 1992;120: 371-9.
14. Moore JC, Arnold DM, Warkentin TE, Warkentin AE, Kelton JG. An algorithm for resolving 'indeterminate' test results in the platelet serotonin release assay for investigation of heparin-induced thrombocytopenia. J Thromb Haemost 2008;6:1595-7.
15. Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008;6:1304-12. (Pubitemid 352016309)
16. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003;163: 2518-24. (Pubitemid 37385796)
17. Eichler P, Budde U, Haas S, Loreth RM, Meyer O, Pachmann U, et al. First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost 1999;81:625-9. (Pubitemid 29178953)
18. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79:1-7. (Pubitemid 28037046)
19. Amiral J, Bridey F, Dreyfus M, Vissoc AM, Fressinaud E, Wolf M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992;68:95-6.
20. Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994;71:247-51. (Pubitemid 24047336)
21. Bakchoul T, Giptner A, Bein G, Santoso S, Sachs UJ. Prospective evaluation of immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2009;7: 1260-5.
22. Warkentin TE, Linkins LA. Immunoassays are not created equal. J Thromb Haemost 2009;7:1256-9.
23. Lindhoff-Last E, Gerdsen F, Ackermann H, Bauersachs R. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol 2001;113:886-90. (Pubitemid 32634754)
24. Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005;146:341-6. (Pubitemid 41712020)
25. Warkentin TE, Sheppard JI, Moore JC, Kelton JG. Use of well-characterized sera for assessment of new diagnostic enzyme-immunoassays for diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2009 Oct 10. [Epub ahead of print].
26. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96:1703-8. (Pubitemid 30661052)
27. Warkentin TE, Sheppard JI. No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure. J Thromb Haemost 2006;4:281-2.
28. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Grei-nacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006;4:759-65.
29. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
30. Kalbfleisch JG. Probability and statistical inference, volume 1: probability. New York: Springer, 1985.
31. Warkentin TE. Heparin-induced skin lesions. Br J Haematol 1996;92:494-7. (Pubitemid 26042948)
32. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia, 4th ed. New York: Informa Healthcare USA, 2007:21-66.
33. Warkentin TE. Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis. Ann Intern Med 2001;135:589-93. (Pubitemid 33010194)
34. Warkentin TE. Pseudo-heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia, 4th ed. New York: Informa Healthcare USA Inc., 2007:261-82.
35. Selleng S, Malowsky B, Strobel U, Wessel A, Itterman T, Wollert HG, et al. A prospective study of platelet count changes and HIT antibodies in post-cardiac surgery patients: early-onset and persisting thrombocytopenia is rarely due to HIT. J Thromb Haemost 2009 Sep 28. [Epub ahead of print].
36. Selleng S, Selleng K, Wollert HG, Muellejans B, Lietz T, Warkentin TE, et al. Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass. J Thromb Haemost 2008;6:428-35. (Pubitemid 351280109)